Coffee consumption can dramatically cut one’s risk of developing hepatocellular carcinoma (HCC), a type of liver cancer, say researchers from Scotland’s University of Edinburgh who…
News
The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) submitted by Bristol-Myers Squibb seeking approval for Opdivo…
CHOLANGITIS
NewsHealth Canada Approves Ocaliva for Autoimmune Liver Disease Patients
Canadian patients with the autoimmune liver disease primary biliary cholangitis (PBC) saw the first approval of a new drug for their condition in more than…
Those with liver cancer that has spread from the colon have a better chance of surgical removal of their liver tumors after treatment with…
Alcohol alters the intestines’ fungus mix, and the imbalance may contribute to the development and progression of alcoholic liver disease (ALD), a study reports. Researchers…
Transplanting 3D bioprinted liver tissue into diseased livers improves liver health in mice, Organovo Holdings revealed. The finding suggests that doctors could use 3D bioprinted…
CHOLANGITIS
NewsIntercept Receives NORD Innovation Award for Ocaliva Therapy to Treat Rare Liver Disease
The National Organization for Rare Disorders (NORD) gave its 2017 Industry Innovation Award to Intercept Pharmaceuticals for the company’s primary biliary cholangitis (PBC) drug …
CHOLESTASIS
NewsAlbireo Plans Phase 3 Trial of A4250 to Treat Children with Life-threatening Liver Disease
Children with progressive familial intrahepatic cholestasis will be able to take part in a Phase 3 clinical trial of A4250’s ability to combat the rare genetic…
Nonalcoholic steatohepatitis, or NASH, might be prevented by treatments able to target certain immune cells, according to a recent study in mice which demonstrated that the condition has…
FATTY LIVER DISEASE
NewsAlbireo Wins 2 U.S. Patents for A4250 Therapy to Treat NASH, Other Liver Diseases
Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis…
Recent Posts
- Living with MASH reminds me to avoid making assumptions
- Particles in grilled meats may trigger liver disease, mouse study finds
- Supporting my oldest son, who’s growing up with a chronically ill sibling
- Human trial testing gene silencing injection therapy for MASH kicks off
- Blood bile acids predict liver outcomes in Alagille syndrome children: Study